Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

Nature Communications

Volumn 6, Issue , 2015, Pages

  Majumder, Biswanath ^a   Baraneedharan, Ulaganathan ^a   Thiyagarajan, Saravanan ^a   Radhakrishnan, Padhma ^a   Narasimhan, Harikrishna ^b   Dhandapani, Muthu ^a   Brijwani, Nilesh ^a   Pinto, Dency D ^a   Prasath, Arun ^a   Shanthappa, Basavaraja U ^a   Thayakumar, Allen ^a   Surendran, Rajagopalan ^c   Babu, Govind K ^d   Shenoy, Ashok M ^d   Kuriakose, Moni A ^e   Bergthold, Guillaume ^f   Horowitz, Peleg ^f,g,h   Loda, Massimo ^f,g   Beroukhim, Rameen ^g,h   Agarwal, Shivani ^b   Sengupta, Shiladitya ^g,i,j   Sundaram, Mallikarjun ^a   Majumder, Pradip K ^a,i   more..

^a MSR Biotech Pvt Ltd   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c STANLEY MEDICAL COLLEGE   (India)

^d KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^e Mazumdar Shaw Cancer Center ^*  (India)

^f HARVARD UNIVERSITY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ Research Resource Center   (India)

^j HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CYTOTOXIC AGENT; LIGAND; MATRIX PROTEIN; SCLEROPROTEIN;

ALGORITHM; BIOENGINEERING; CANCER; DISEASE TREATMENT; DRUG; HETEROGENEITY; MACHINERY; NUMERICAL MODEL; TUMOR;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLOGOUS SERUM; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANSCRIPT TECHNOLOGY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EX VIVO STUDY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PERSONALIZED MEDICINE; SENSITIVITY AND SPECIFICITY; SERUM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR HETEROGENEITY; TUMOR MICROENVIRONMENT; ANALYSIS OF VARIANCE; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; LIQUID CHROMATOGRAPHY; METABOLISM; PREDICTIVE VALUE; PROCEDURES; SCANNING ELECTRON MICROSCOPY; TANDEM MASS SPECTROMETRY; TISSUE ENGINEERING;

ALGORITHMS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DNA MUTATIONAL ANALYSIS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MACHINE LEARNING; MICROSCOPY, ELECTRON, SCANNING; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; TANDEM MASS SPECTROMETRY; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT;

EID: 84924024023     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7169     Document Type: Article

References (70)

1. Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J. & Bardelli, A. Biomarkers predicting clinical outcome of epidermal growth factor receptortargeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101, 1308-1324 (2009).
2. van't Veer, L. J. & Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570 (2008).
3. Samson, D. J., Seidenfeld, J., Ziegler, K. & Aronson, N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 22, 3618-3630 (2004).
4. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
5. Foekens, J. A. et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24, 1665-1671 (2006).
6. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
7. Van Cutsem, E. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
8. Nakasone, E. S. et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503 (2012).
9. McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483-489 (2010).
10. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
11. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
12. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
13. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548 (2013).
14. Pontiggia, O. et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Res. Treat. 133, 459-471 (2012).
15. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662-668 (1999).
16. Yamada, K. M. & Cukierman, E. Modeling tissue morphogenesis and cancer in 3D. Cell 130, 601-610 (2007).
17. Weaver, V. M. et al. beta4 integrin-dependent formation of polarized threedimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205-216 (2002).
18. Wang, F. et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J. Natl Cancer Inst. 94, 1494-1503 (2002).
19. Sharma, S. V., Haber, D. A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241-253 (2010).
20. Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl Acad. Sci. USA 107, 8352-8356 (2010).
21. Ridky, T. W., Chow, J. M., Wong, D. J. & Khavari, P. A. Invasive threedimensional organotypic neoplasia from multiple normal human epithelia. Nat. Med. 16, 1450-1455 (2010).
22. Jung, P. S. et al. Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res. 33, 1029-1034 (2013).
23. Karagiannis, G. S. et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 3, 267-285 (2012).
24. Genovese, L. et al. Cellular localization, invasion, and turnover are differently influenced by healthy and tumor-derived extracellular matrix. Tissue Eng. Part A 20, 2005-2018 (2014).
25. Mazzoleni, G., Di Lorenzo, D. & Steimberg, N. Modelling tissues in 3D: the next future of pharmaco-toxicology and food research? Genes Nutr. 4, 13-22 (2009).
26. Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007).
27. Benedettini, E. et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 177, 415-423 (2010).
28. Frederick, M. J. et al. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am. J. Pathol. 178, 548-571 (2011).
29. Puliyappadamba, V. T. et al. Opposing effect of EGFRWT on EGFRvIIImediated NF-kappaB activation with RIP1 as a cell death switch. Cell Rep. 4, 764-775 (2013).
30. Baudhuin, L. M. et al. S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J. 18, 341-343 (2004).
31. Sheng, Q. et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17, 298-310 (2010).
32. Yamada, T. et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin. Cancer Res. 18, 3592-3602 (2012).
33. Goh, L. K. & Sorkin, A. Endocytosis of receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 5, a017459 (2013).
34. Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362, 875-885 (2010).
35. Young, M. R. et al. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum. Immunol. 62, 332-341 (2001).
36. Akervall, J. et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin. Cancer Res. 10, 8204-8213 (2004).
37. Chang, J. C. et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23, 1169-1177 (2005).
38. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
39. Siu, L. L. et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J. Clin. Oncol. 31, 2477-2484 (2013).
40. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
41. Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
42. Kim, J. et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J. Clin. Oncol. 23, 2744-2753 (2005).
43. Burnouf, T. et al. Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. Biologicals. 40, 21-30 (2012).
44. Gerlach, M. M. et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br. J. Cancer. 110, 479-488 (2014).
45. Ashley, N., Jones, M., Ouaret, D., Wilding, J. & Bodmer, W. F. Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalized therapeutic assays. J. Pathol. 234, 34-45 (2014).
46. Sekine, H. et al. In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels. Nat. Commun. 4, 1399 (2013).
47. Collins, K. B., Patterson, B. K., Naus, G. J., Landers, D. V. & Gupta, P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6, 475-479 (2000).
48. Hirt, C. et al. "In vitro" 3D models of tumor-immune system interaction. Adv. Drug. Deliv. Rev. 79-80C, 145-154 (2014).
49. Suchy, S. L., Hancher, L. M., Wang, D., Ervin, Jr. P. R. & Brower, S. L. Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer. Cancer Biol. Ther. 11, 1059-1064 (2011).
50. Radhakrishnan, P. et al. Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers. Cancer Res. 73, 1118-1127 (2013).
51. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
52. Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601 (2004).
53. Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940 (2011).
54. Shumiya, T. et al. Evidence for the therapeutic potential of ex vivo expanded human endothelial progenitor cells using autologous serum. Circ. J. 74, 1006-1013 (2010).
55. Gohji, K. et al. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J. Clin. Oncol. 18, 2963-2971 (2000).
56. Leitzel, K. et al. Elevated plasma platelet-derived growth factor B-chain levels in cancer patients. Cancer Res. 51, 4149-4154 (1991).
57. Zhang, Z., Dong, Z., Lauxen, I. S., Filho, M. S. & Nor, J. E. Endothelial cellsecreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res. 74, 2869-2881 (2014).
58. Seshadri, M. et al. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol. Ther. 8, 2275-2283 (2009).
59. Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275-1281 (2008).
60. Hofmann, D. et al. WSG ADAPT-adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials 14, 261 (2013).
61. Posner, M. R. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 10(Suppl 3): 11-19 (2005).
62. Uriel, S. et al. Extraction and assembly of tissue-derived gels for cell culture and tissue engineering. Tissue Eng. Part C Methods 15, 309-321 (2009).
63. Ngoka, L. C. Sample prep for proteomics of breast cancer: proteomics and gene ontology reveal dramatic differences in protein solubilization preferences of radioimmunoprecipitation assay and urea lysis buffers. Proteome Sci. 6, 30 (2008).
64. Naba, A. et al. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer 14, 518 (2014).
65. Zeng, X. et al. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J. Proteome Res. 9, 6440-6449 (2010).
66. Zhou, W., Liotta, L. A. & Petricoin, E. F. The spectra count label-free quantitation in cancer proteomics. Cancer Genomics Proteomics 9, 135-142 (2012).
67. Zhang, G. et al. Protein quantitation using mass spectrometry. Methods Mol. Biol. 673, 211-222 (2010).
68. Matzke, M. M. et al. A comparative analysis of computational approaches to relative protein quantification using peptide peak intensities in label-free LC-MS proteomics experiments. Proteomics 13, 493-503 (2013).
69. Narasimhan, N. & Agarwal, S. SVMpAUC tight. A new support vector method for optimizing partial AUC based on a tight convex upper bound. In Proceedings of the 19th ACM SIGKDD Conference on Knowledge Discovery and Data Mining 167-175 (2013).
70. Chu, W. & Keerthi, S. S. Support vector ordinal regression. Neural Comput. 19, 792-815 (2007).